Mechanisms and regulation of vitamin C uptake: studies of the hSVCT systems in human liver epithelial cells.
Humans use two sodium-ascorbate cotransporters (hSVCT1 and hSVCT2) for transporting the dietary essential micronutrient ascorbic acid, the reduced and active form of vitamin C. Although the human liver plays a pivotal role in regulating and maintaining vitamin C homeostasis, vitamin C transport physiology and regulation of the hSVCT systems in this organ have not been well defined. Thus, this research used a human hepatic cell line (HepG2), confirming certain results with primary human hepatocytes and determined the initial rate of ascorbic acid uptake to be Na(+) gradient, pH dependent, and saturable as a function of concentration over low and high micromolar ranges. Additionally, hSVCT2 protein and mRNA are expressed at higher levels in HepG2 cells and native human liver, and the cloned hSVCT2 promoter has more activity in HepG2 cells. Results using short interfering RNA suggest that in HepG2 cells, decreasing hSVCT2 message levels reduces the overall ascorbic acid uptake process more than decreasing hSVCT1 message levels. Activation of PKC intracellular regulatory pathways caused a downregulation in ascorbic acid uptake not mediated by a single predicted PKC-specific amino acid phosphorylation site in hSVCT1 or hSVCT2. However, PKC activation causes internalization of hSVCT1 but not hSVCT2. Examination of other intracellular regulatory pathways on ascorbic acid uptake determined that regulation also potentially occurs by PKA, PTK, and Ca(2+)/calmodulin, but not by nitric oxide-dependent pathways. These studies are the first to determine the overall ascorbic acid uptake process and relative expression, regulation, and contribution of the hSVCT systems in human liver epithelial cells.
Veterans Affairs Medical Center, Long Beach, CA 90822, USA. jreidlin@uci.edu
Jack C
JC
Reidling
Veedamali S
VS
Subramanian
Tamara
T
Dahhan
Mohammed
M
Sadat
Hamid M
HM
Said
D001205:Ascorbic Acid / Q000378:metabolism* / Q000494:pharmacology; D019819:Budesonide / Q000494:pharmacology; D045744:Cell Line, Tumor; D003683:Dehydroascorbic Acid / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004847:Epithelial Cells / Q000378:metabolism; D005786:Gene Expression Regulation; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism*; D015735:Mifepristone / Q000494:pharmacology; D029363:Organic Anion Transporters, Sodium-Dependent / Q000502:physiology*; D011401:Promoter Regions, Genetic / Q000502:physiology; D011493:Protein Kinase C / Q000502:physiology; D034741:RNA, Small Interfering / Q000235:genetics; D060347:Sodium-Coupled Vitamin C Transporters; D027981:Symporters / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014162:Transfection
D029363:Organic Anion Transporters, Sodium-Dependent; D034741:RNA, Small Interfering; D060347:Sodium-Coupled Vitamin C Transporters; D027981:Symporters; C005056:isoascorbic acid; D015735:Mifepristone; D019819:Budesonide; D003907:Dexamethasone; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D001205:Ascorbic Acid; D003683:Dehydroascorbic Acid